At the 2026 ASTRO annual meeting, UCLA researchers are presenting evidence that cancer radiation therapy need not be a uniform prescription handed to all patients alike. Through genetic testing and MRI-guided precision, their work across prostate, bile duct, and head and neck cancers reveals that individual biology shapes both vulnerability and survival in ways that standard protocols have long ignored. The deeper implication is not merely clinical but ethical: if we can know in advance who will suffer most, the obligation to act on that knowledge becomes difficult to defer.
UCLA radiation oncology advances personalized cancer treatment at ASTRO 2026
Research demonstrates reduced severe urinary side effects in prostate cancer patients and improved survival outcomes in bile duct cancer patients through personalized radiation approaches.
36 times more likely to develop lasting urinary problems
Mark
So the PROSTOX test—it's identifying genetic risk before treatment even starts. How reliable is that prediction?
Mimi
The prospective trial showed it worked in practice, not just theory. When doctors used PROSTOX to guide treatment decisions, they actually reduced severe urinary side effects. And when they looked back at 457 men from earlier trials, the high-risk group was 36 times more likely to develop lasting problems.
Luke
But I want to be careful here. The prospective trial showed it reduced side effects—do we know by how much? The source doesn't give us that number. We know the 36-times figure comes from retrospective data, which is weaker than a prospective trial.
Mark
Fair point. So what's the practical difference for a patient? If you're high-risk, what changes?
Mimi
Instead of getting stereotactic body radiation—a concentrated dose over a few sessions—you get a longer course of gentler radiation. It takes more time, but it spares you years of urinary complications.
Luke
And we should note: this is prostate cancer specifically. The head and neck findings are separate, and they're about predicting side effects and survival, not yet about changing treatment based on the test.
Mark
The bile duct cancer story seems different entirely. These are people waiting for transplants.
Mimi
Right. They can't have surgery to remove the cancer, so they're stuck waiting for a donor organ. The MRI-guided radiation lets them control the tumor while they wait. Eleven of 38 patients got transplants, and they lived much longer than those who didn't.
Luke
That's important context—only 11 of 38 got transplants. We don't know why the others didn't. Were they too sick? Did they die waiting? The source doesn't say.
Mark
But for the ones who did get transplants, the results sound remarkable.
Mimi
They do. Median survival of 150 weeks versus 94 weeks for those who didn't get transplants. And more than a third had no cancer left in the liver when it was removed.
Luke
That's a real difference. Though we should note: this is a 14-year retrospective review of 38 patients. It's not a randomized trial. We're seeing what happened, not proving the radiation caused the better outcomes.
Mark
So what's the takeaway? Are these treatments ready for widespread use?
Mimi
The genetic testing seems close—it's already being used to guide prostate cancer treatment. The bile duct findings suggest MRI-guided radiation is well-tolerated and effective, but more research would help confirm it.
Luke
And the head and neck findings are still predictive models, not yet proven to change outcomes if doctors act on them. That's the next step.
O Pulso
- A genetic test called PROSTOX identifies prostate cancer patients who are 36 times more likely to suffer lasting urinary damage from radiation — a risk gap so wide it demands a different treatment path entirely.
- In head and neck cancer, patients flagged as high-risk by genetic models survived a median of just 2.25 years compared to 4.46 years for lower-risk patients, exposing how much clinical information alone has been leaving on the table.
- Bile duct cancer patients waiting for liver transplants are receiving MRI-guided radiation so precise that over one-third arrived at surgery with no detectable cancer remaining in the organ.
- UCLA faculty are receiving ASTRO's highest honors this week, signaling that the field is formally recognizing a shift away from one-size-fits-all protocols toward treatment built on individual biology.
- The trajectory points toward genetic testing becoming routine before any radiation course begins — changing not just how oncologists treat patients, but how they prepare them for what lies ahead.
At the 2026 ASTRO annual meeting, UCLA researchers are presenting evidence that cancer radiation therapy need not be a uniform prescription handed to all patients alike. Through genetic testing and MRI-guided precision, their work across prostate, bile duct, and head and neck cancers reveals that individual biology shapes both vulnerability and survival in ways that standard protocols have long ignored. The deeper implication is not merely clinical but ethical: if we can know in advance who will suffer most, the obligation to act on that knowledge becomes difficult to defer.
At this week's American Society for Radiation Oncology annual meeting, UCLA's Jonsson Comprehensive Cancer Center is presenting research built around a deceptively simple premise: patients are not interchangeable, and radiation therapy should not treat them as though they are. Across three cancer types, UCLA teams are showing that genetic information can predict who will be harmed by standard treatment — and that acting on that information changes outcomes in measurable, sometimes dramatic ways.
The clearest demonstration involves prostate cancer. A genetic test called PROSTOX, developed by Dr. Amar Kishan and Dr. Joanne Weidhaas, identifies men with inherited variations that make them far more susceptible to long-term urinary damage after high-dose focused radiation. In a prospective trial, men flagged as high-risk were steered toward a gentler, longer course of treatment — and their rates of moderate to severe urinary side effects dropped significantly. A review of data from 457 men across four earlier trials confirmed the stakes: high-risk patients were roughly 36 times more likely to develop lasting urinary problems than those at low risk.
The same logic is being applied to head and neck cancer, where Weidhaas's team analyzed genetic and clinical data from 171 patients. Genetic markers, layered onto standard clinical factors, predicted both immediate and delayed side effects more accurately than clinical data alone. The survival gap was striking: patients identified as high-risk had a median survival of 2.25 years, compared with 4.46 years for those at lower risk — a difference large enough to suggest that genetic profiling could eventually reshape monitoring and treatment decisions entirely.
A third study addressed bile duct cancer patients waiting for liver transplants — a population with few options and little margin for error. Dr. Trudy Wu reviewed 14 years of outcomes for 38 patients who received MRI-guided radiation while on transplant waiting lists. The precision of MRI guidance allowed high doses to reach tumors while sparing surrounding tissue. Patients who eventually received transplants lived a median of about 150 weeks, compared with 94 weeks for those who did not. More than one-third of transplant recipients had no detectable cancer remaining when surgeons removed the liver.
The meeting is also recognizing the people behind this shift. Dr. Daniel Low is receiving ASTRO's Gold Medal for a career in medical physics; Dr. Luca Valle and Dr. Jie Deng received early-career honors. Together, the awards and the research point in the same direction: radiation oncology is moving toward treatment plans shaped by individual biology, and the question is no longer whether genetic testing belongs in this field, but how quickly it can become routine.
At the 2026 American Society for Radiation Oncology annual meeting this week, researchers from UCLA's Jonsson Comprehensive Cancer Center are presenting findings that reshape how doctors might treat cancer by tailoring radiation therapy to individual genetic profiles. The work spans three cancer types—prostate, bile duct, and head and neck—and centers on a simple but powerful idea: not all patients respond to radiation the same way, and knowing which ones are vulnerable to serious side effects before treatment begins could spare them months or years of suffering.
The most concrete example comes from a study led by Dr. Amar Kishan and Dr. Joanne Weidhaas on a genetic test called PROSTOX. The test identifies men with prostate cancer who carry inherited genetic variations that make them far more susceptible to long-term urinary damage after stereotactic body radiation therapy, a focused, high-dose form of treatment. In a prospective clinical trial, men flagged as high-risk by PROSTOX were directed toward a longer, gentler course of radiation instead of the concentrated dose. The result: moderate to severe urinary side effects dropped significantly. When researchers looked back at data from four earlier trials involving 457 men, the numbers were stark—patients classified as high-risk by PROSTOX were roughly 36 times more likely to develop lasting urinary problems than those at low risk. For men facing prostate cancer treatment, this means the difference between a few years of manageable symptoms and a decade of serious complications.
The same principle is being tested in head and neck cancer. Weidhaas's team analyzed genetic and clinical information from 171 patients treated with radiation and cisplatin chemotherapy. They found that genetic markers, when combined with standard clinical factors, predicted both immediate and delayed treatment side effects better than clinical information alone. More strikingly, the genetic models identified patients at much higher risk of early death—those predicted to be at high risk had a median survival of 2.25 years, compared with 4.46 years for those at lower risk. The gap suggests that genetic testing could eventually help oncologists decide which patients need more aggressive monitoring or entirely different treatment strategies.
A third line of research addresses a different problem: patients with bile duct cancer who cannot have surgery but are waiting for a liver transplant. Dr. Trudy Wu reviewed 14 years of data on 38 patients who received MRI-guided stereotactic body radiation therapy while on transplant waiting lists. The precision of MRI guidance allowed doctors to deliver high doses of radiation directly to the tumor while sparing surrounding tissue. Eleven of those patients eventually received transplants and lived significantly longer than those who did not—a median of about 150 weeks compared with 94 weeks. Even more remarkable, more than one-third of the transplant patients had no detectable cancer remaining in the liver when surgeons removed the organ. The radiation was also well-tolerated, with most patients reporting no side effects at all.
The research is being recognized at the highest levels of the field. Dr. Daniel Low, a professor of medical physics at UCLA, is receiving the 2026 ASTRO Gold Medal, the organization's highest honor, for his career contributions to radiation oncology. Dr. Luca Valle has been awarded the ASTRO-PCF Young Investigator Award, and Dr. Jie Deng received an American Cancer Society Clinician Scientist Development Grant. These awards reflect a broader shift in how radiation oncology is evolving—away from one-size-fits-all protocols and toward treatment plans built on individual biology. Dr. Michael Steinberg, chair of radiation oncology at UCLA, noted that the research demonstrates how advances in technology, biology, and clinical science are reshaping cancer care. The presentations this week suggest that within a few years, genetic testing could become routine before radiation therapy, allowing doctors to predict who will suffer serious side effects and adjust their approach accordingly—potentially transforming not just how patients are treated, but how they are counseled about what to expect.
Citações Notáveis
The research our faculty are presenting this year reflects the breadth of innovation across our department, from more personalized approaches to treatment to new ways of combining radiation with other therapies.— Dr. Michael Steinberg, chair of radiation oncology at UCLA
Quer a matéria completa?
Leia o original em News-Medical ↗